Table 1: Baseline characteristics by prophylactic group.
|
|
Group A (IV Cefoxitin + pocipro) |
Group B (Oral FT) |
Total |
p |
|
Age (m ± SD) |
66.69 ± 8.6 |
68.95 ± 9.1 |
|
0.02 |
|
Obesity (n, %) |
38 (21.8) |
34 (24.3) |
72 (16.9) |
0.61 |
|
Diabetes Mellitus (n, %) |
31 (12.9) |
43 (23.5) |
74 (17.4) |
0.005 |
|
Previous SLUTI1 (n, %) |
|
|
|
|
|
No previous SLUTI |
166 (70) |
166 (64.1) |
282 (66.3) |
0.20 |
|
a-blockers2 (n, %) |
58 (24.5) |
44 (24.3) |
102 (24) |
1.00 |
|
5-ARI3 (n, %) |
10 (4.2) |
16 (8.8) |
26 (6.1) |
0.07 |
|
Urinary Catheter4 (n, %) |
3 (1.3) |
5 (2.8) |
8 (1.8) |
0.30 |
|
Repeat Biopsies5 (n, %) |
52 (21.6) |
28 (15.2) |
80 (18.8) |
0.09 |
|
ACO/AAS6 (n, %) |
36 (15) |
18 (9.8) |
54 (12.7) |
0.11 |
|
PSA (m ± SD) |
26.4 ± 151.2 |
43.21 ± 171.95 |
|
0.23 |
|
Prostate Vol.7 (m ± SD) |
51.10 ± 29.2 |
56.27 ± 31.5 |
|
0.12 |
|
Cores8 (m ± SD) |
11.8 ± 5.5 |
11.97 ± 2.4 |
|
0.09 |
1Symptoms of lower urinary tract infection before the TRUS; 2Alpha-blockers +/- anticholinergics / beta-3 agonists.
35-ARIS, 5α-reductase inhibitors, +/- anticholinergics /beta-3-agonists; 4Those wearing urinary catheter at the time of the TRUS; 5Repeat biopsies: 1 or more previous biopsies; 6Long-term anticoagulation or antiplatelet therapy; 7Prostate volume measured by transrectal ultrasound; 8Overall number of core biopsies taken during the TRUS procedure.